Needham & Company LLC Reiterates “Hold” Rating for Inogen (NASDAQ:INGN)

Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN) in a research note released on Friday morning,Benzinga reports.

Separately, StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th.

Inogen Price Performance

Shares of Inogen stock traded up $1.63 during trading on Friday, hitting $11.09. 937,866 shares of the company’s stock traded hands, compared to its average volume of 158,190. Inogen has a twelve month low of $4.59 and a twelve month high of $13.33. The company has a market cap of $263.04 million, a PE ratio of -4.93 and a beta of 1.04. The firm’s fifty day moving average price is $9.95 and its 200 day moving average price is $9.39.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.31. The company had revenue of $88.77 million for the quarter, compared to analyst estimates of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The company’s revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.42) EPS. As a group, equities research analysts anticipate that Inogen will post -1.92 earnings per share for the current year.

Institutional Trading of Inogen

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Inogen in the 1st quarter worth approximately $129,000. Oppenheimer Asset Management Inc. acquired a new position in Inogen in the first quarter worth $121,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Inogen during the first quarter worth $81,000. Inspire Advisors LLC bought a new stake in shares of Inogen during the first quarter worth $255,000. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Inogen by 27.3% in the first quarter. Tocqueville Asset Management L.P. now owns 93,350 shares of the medical technology company’s stock valued at $753,000 after buying an additional 20,000 shares in the last quarter. 89.94% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.